PARP inhibition — not all gene mutations are created equal

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Preliminary results from TRITON2 demonstrate efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in ~50% of patients with metastatic castration-resistant prostate cancer and inactivation of BRCA1/BRCA2. However, those with ATM and CDK12 mutations do not seem to benefit. An improved homologous recombination deficiency test must be developed and alternative treatments defined for these subsets of patients.

Original languageEnglish (US)
Pages (from-to)4-6
Number of pages3
JournalNature Reviews Urology
Issue number1
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'PARP inhibition — not all gene mutations are created equal'. Together they form a unique fingerprint.

Cite this